CTOR

Citius Oncology is a single-asset, pre-revenue specialty biopharma whose entire future rides on LYMPHIR (denileukin diftitox), an FDA-approved CTCL immunotherapy that only launched commercially in December 2025. There is no revenue line in any year shown (FY2022–FY2025), while losses have widened every year — FY2025 net loss of -$24.8M (YoY -17.1%) and operating loss of -$23.5M, with ROE of -55.2%. This is a story stock with no financial results yet to underwrite.

The balance sheet is the disqualifier. The 10-K carries an explicit going-concern paragraph: management estimated cash sufficient only 'through March 2026' even after the $6.0M raised by Citius Pharma in October 2025 and the $18.0M raised in December 2025. Given today is July 2026, that stated runway has already lapsed, so continued operation depends entirely on further capital the company says it 'can provide no assurances' of raising 'on acceptable terms, or at all.' Cash was just $3.92M at FY2025, current liabilities of $49.5M swamp current assets of $27.5M (a ~$22M working-capital hole), liabilities/equity has jumped to 1.25x as total liabilities grew +46.7%, and a $19.75M milestone still owed to Dr. Reddy's looms. Shares outstanding already rose 18.5% in a year, so any survival financing means heavy, price-insensitive dilution at a $0.68 quote.